PT-141 Nasal Spray: What the Evidence Shows

9 min readWritten by Protocol Health Editorial TeamMedically reviewed by Richard Dentico, MDPublished Updated

PT-141 nasal spray is a compounded form of bremelanotide, and it is not the FDA-approved product. Early studies suggest a spray can produce an effect, but the large trials behind the approved drug tested an injection.

PT-141 Nasal Spray: What the Evidence Shows
Here’s what we’ll cover

Key takeaways

  • PT-141 nasal spray is a compounded, unapproved form of bremelanotide. The only approved product is the Vyleesi injection (Vyleesi label).
  • The approval rests on injection trials. Phase 3 RECONNECT studied the subcutaneous form (Dhillon et al., 2019).
  • Nasal data are small and early. An intranasal study measured erectile responses in men (Diamond et al., 2004).
  • Blood pressure is the key safety issue. The label contraindicates it in uncontrolled hypertension or cardiovascular disease (Vyleesi label).

Short Answer

What Is PT-141 Nasal Spray?

PT-141 nasal spray is a compounded form of bremelanotide, a peptide that acts on melanocortin receptors in the brain. It is not FDA-approved. The only approved bremelanotide product is Vyleesi, a subcutaneous injection for premenopausal women with acquired, generalized low sexual desire that causes distress.

PT-141 reached approval as an injection after phase 3 trials of that form, and the spray has no comparable phase 3 record. If you are weighing it, our short assessment is the first step.

So a physician may prescribe PT-141 nasal spray, but it rests on thinner evidence than the approved injection, and that gap should shape the decision.

Does It Work

Does PT-141 Work as a Nasal Spray?

Whether PT-141 works as a nasal spray is unproven: small studies showed short-term responses, but no large, reliable trial has shown that it treats low desire by that route. The evidence is early. In one crossover study of 18 premenopausal women with sexual arousal disorder, more reported moderate or high desire after a single 20 mg intranasal dose than after placebo. Measured vaginal blood flow did not change. Its lead authors worked at the drug's developer, and it tested one dose in a clinic.

In men, a study of intranasal PT-141 found an erectile response on lab monitoring at doses above 7 mg. A 19-man crossover study found a stronger response when 7.5 mg intranasal PT-141 was combined with low-dose sildenafil than with sildenafil alone. Both studied men who were healthy or already responded to these pills, ran in a lab, and were led by authors at the drug's developer. Those doses describe what the studies gave and are not instructions.

Two larger nasal papers deserve caution. A 342-man trial in sildenafil non-responders reported benefit, but its journal later issued an expression of concern. A trial in women by the same author was retracted because its results could not be verified. We do not rest any conclusion on them, and you should discount pages that do.

The honest answer is that PT-141 nasal spray has shown a signal in small studies, without proof of how well it works in everyday use.

Spray vs Injection

How Does PT-141 Nasal Spray Compare With the Injection?

PT-141 nasal spray compares poorly with the injection on evidence, while it may appeal to people who dislike needles. In our search of PubMed and ClinicalTrials.gov (November 2026), we found no randomized trial comparing the two routes directly. That search is not exhaustive, but on what we found, claims that one is faster or stronger are not established. The developer moved from the nasal form to the injection after those blood pressure and absorption findings. The phase 3 RECONNECT trials enrolled 1,267 women and tested only a subcutaneous dose.

QuestionVyleesi injectionCompounded nasal spray"Research use" spray sold online
FDA-approved?Yes, for one labeled useNoNo
Prescription from a clinician?YesYesOften none
Phase 3 trials of that form?YesNoNo
Dose and purity reviewed by FDA?YesNoNo
Labeled warnings written for it?YesNo; the injection's label is the closest guideNo

The approved label's numbers come from the injection, so they do not transfer neatly to a spray. FDA says compounded drugs are not FDA-approved and that it does not verify their safety, effectiveness or quality before marketing. A spray may still be reasonable for a given patient, and that is a judgment for a physician who has your history.

Bottom line: the injection has the stronger evidence and the spray has no needle, and neither fact makes the spray equivalent to the injection.

Onset

How Long Does PT-141 Nasal Spray Take to Kick In?

PT-141 nasal spray may take about 30 minutes to kick in, based on limited data from men in a lab. In the intranasal study, blood levels peaked at a median of 30 minutes and the first erection came at roughly 30 minutes. That says little about desire at home, and we found no comparable timing data for women using a spray.

The Vyleesi label directs use at least 45 minutes before anticipated sexual activity, and it says the duration of effect after each dose is unknown. It also warns against more than one dose in 24 hours because of additive blood pressure effects. A timeline quoted with confidence for a spray goes beyond what has been measured, so ask your prescriber what to expect from PT-141 nasal spray.

Side Effects

What Are the Side Effects of PT-141 Nasal Spray?

PT-141 nasal spray has a specific blood pressure history. In small studies, flushing and nausea were most common, but the developer later reported blood pressure increases in some patients on the nasal form, along with significant variation in blood levels, and stopped pursuing it as a first-line therapy. That variation means a given spray dose may not produce a predictable exposure. The injection's label gives the fuller picture of what bremelanotide can do, though a spray's rates may differ:

  • Nausea: reported by 40% of patients in the phase 3 trials. It needed medication in 13% and led 8% to stop.
  • Flushing and headache: flushing affected 20% and headache 11% on the injection, compared with 0.3% and 1.9% on placebo. Vomiting affected 4.8%.
  • Blood pressure: maximal rises of about 6 mmHg systolic and 3 mmHg diastolic with a lower heart rate, usually resolving within 12 hours of a dose.
  • Skin darkening: focal hyperpigmentation in 1% of patients using up to 8 doses a month, including the face, gums and breasts. Risk is higher with darker skin and with daily dosing: 38% developed it after 8 straight daily doses in one study. Resolution was not confirmed in all patients after stopping.

Nasal irritation is a reasonable thing to raise with your prescriber, because a spray touches the nasal lining and the injection's label cannot speak to that. Treat these PT-141 side effects as the starting point for a safety review, not as a complete list for a nasal product.

Who Should Avoid It

Who Should Avoid PT-141 Nasal Spray?

People with uncontrolled high blood pressure or known cardiovascular disease should avoid PT-141 nasal spray, because the label contraindicates bremelanotide in both. The label also says it is not recommended for those at high risk of cardiovascular disease, and it advises stopping if pregnancy is suspected and using effective contraception during treatment.

Medications matter too. Bremelanotide may slow stomach emptying, so it can affect oral drugs, and the label says to avoid it with oral naltrexone products used for alcohol or opioid addiction. Tell your prescriber everything you take before starting PT-141 nasal spray.

Men and Women

Is PT-141 Nasal Spray for Men or Women?

PT-141 nasal spray is used by both men and women, but every such use involves a compounded, unapproved product. The label states that Vyleesi is not indicated for men or postmenopausal women and is not indicated to enhance sexual performance. For PT-141 for men, the nasal evidence above mostly measures erections, not desire.

For PT-141 for women, the strongest data are from the injection, and only in premenopausal women, so they do not establish benefit after menopause. RECONNECT found statistically significant gains in desire and less related distress, though the average differences from placebo were modest (0.35 and -0.33 points on the two scales). The trials were funded by the drug's developers. A broad meta-analysis of female sexual dysfunction drugs attributed about 68% of treatment effect to placebo, so expectations should stay measured. In women who stayed on it, a 52-week extension found no new safety signals, but only 272 of 684 completed it.

Low desire also has causes a peptide will not fix, such as medications, hormones, mood and relationship strain, so PT-141 nasal spray for men or women should follow a review of those causes. See low testosterone in women, signs of low testosterone and no morning wood.

Buying Online

Can You Buy PT-141 Nasal Spray Online or Over the Counter?

You cannot legitimately buy PT-141 nasal spray over the counter, because bremelanotide treatment requires a prescription. Online, you will see two very different things: a telehealth prescription filled by a compounding pharmacy, and marketplace sprays with no prescriber at all. Products sold for "research use" are not made for human use. Our guide to pharmaceutical-grade versus research-grade peptides explains how to tell them apart.

Ask who prescribes it, which licensed pharmacy compounds it, and who follows up on your blood pressure. If an online seller of PT-141 nasal spray cannot answer those three questions, do not use the product. Our guide to whether peptides are legal explains the categories.

Our Approach

PT-141 Nasal Spray at Protocol Health

Protocol Health approaches PT-141 nasal spray as one option a provider may prescribe after reviewing your desire concerns, hormones, medications, blood pressure and history. We offer PT-141 as a vial or a nasal spray, so we have a commercial interest in this topic. Visits take place at our Scarsdale clinic or by telehealth in New York, New Jersey, Connecticut, Florida and California.

Your provider may recommend the approved injection, another approach, or no medication at all, and no result is guaranteed. You can also read about boosting libido without a prescription, or take the Protocol Health quiz to start a consultation. This guide is educational and is not medical advice, and the decision on PT-141 nasal spray belongs with a licensed provider who knows your history.

Bottom Line

The Bottom Line

PT-141 nasal spray rests on thinner evidence than the approved injection, and that gap should shape the decision.

  • Nausea is common. 40% reported it in the injection's phase 3 trials (Vyleesi label).
  • Blood pressure rose with the nasal form. The developer reported it (Palatin).
  • Compounded is not approved. The FDA does not review compounded drugs before marketing (FDA).
  • Never buy 'research use' spray. Identity and sterility are unknown.
  • Look for the cause of low desire first. Hormones, medications and mood all matter.

FAQ

Frequently Asked Questions

Is PT-141 nasal spray FDA-approved?

PT-141 nasal spray is not FDA-approved. The only approved bremelanotide product is Vyleesi, an injection for premenopausal women with acquired, generalized low sexual desire. Compounded sprays do not go through FDA approval.

Is PT-141 nasal spray as good as the injection?

Whether PT-141 nasal spray is as good as the injection is unknown, because our PubMed and ClinicalTrials.gov search found no randomized trial comparing them directly. The injection has phase 3 data, and the spray has only small early studies.

Does PT-141 nasal spray treat erectile dysfunction?

PT-141 nasal spray is not approved to treat erectile dysfunction. Small lab studies measured erectile responses in men, but no spray is approved for any use, and a provider should first review why erections or desire have changed.

How often can PT-141 nasal spray be used?

How often PT-141 nasal spray can be used is a question for your prescriber, as no approved schedule exists for a spray. The injection's label advises no more than one dose in 24 hours and no more than 8 a month.

Is PT-141 the same as bremelanotide?

PT-141 is the same molecule as bremelanotide. PT-141 was its development name, and Vyleesi is the brand name of the approved injection. A compounded spray contains the same active ingredient but is a different, unapproved product.

Explore

Related at Protocol Health

Talk to a provider about PT-141

Medical disclaimer

This article is for education only and is not medical advice, diagnosis, or treatment. Talk to a licensed clinician before starting, stopping, or changing any medication.

Important safety information

References

  1. VYLEESI (bremelanotide) injection prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf
  2. Dhillon S et al., 2019. Bremelanotide: First Approval. Drugs. PMID 31429064. https://pubmed.ncbi.nlm.nih.gov/31429064/
  3. Diamond LE et al., 2004. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. PMID 14963471. https://pubmed.ncbi.nlm.nih.gov/14963471/
  4. Diamond LE et al., 2006. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. PMID 16839319. https://pubmed.ncbi.nlm.nih.gov/16839319/
  5. Diamond LE et al., 2005. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology. PMID 15833522. https://pubmed.ncbi.nlm.nih.gov/15833522/
  6. Safarinejad MR et al., 2008. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol. PMID 18206919. https://pubmed.ncbi.nlm.nih.gov/18206919/
  7. Safarinejad MR, 2008. RETRACTED: Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study. J Sex Med. PMID 18179455. https://pubmed.ncbi.nlm.nih.gov/18179455/
  8. Kingsberg SA et al., 2019. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. PMID 31599840. https://pubmed.ncbi.nlm.nih.gov/31599840/
  9. US Food and Drug Administration. Compounding and the FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
  10. Palatin Technologies. Press release: positive safety results in subcutaneous bremelanotide trial in men. https://palatin.com/press_releases/palatin-technologies-inc-announces-positive-safety-results-in-subcutaneous-bremelanotide-trial-in-men/
Show all 12 references
  1. Weinberger JM et al., 2018. Female Sexual Dysfunction and the Placebo Effect: A Meta-analysis. Obstet Gynecol. PMID 29995725. https://pubmed.ncbi.nlm.nih.gov/29995725/
  2. Simon JA et al., 2019. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. PMID 31599847. https://pubmed.ncbi.nlm.nih.gov/31599847/

Why trust our physicians

Every article is reviewed by a licensed physician on our medical team and is kept current by our editorial team. Read our editorial policy and our medical review process.

Medically reviewed by
Richard Dentico, MD on
Written by
Protocol Health Editorial Team
First published
Last updated

See an error? Email care@protocolhealthmd.com and we will review it.

More on Sexual Health

All Sexual Health articles →